StockDuty ← Dashboard Nov 05, 2026 06:44 AM ET
SignalFDA/Bio

Moderna Earnings Preview: The Melanoma Breakthrough Is Real, But $221 Is Way Too Much

Moderna earnings preview questions $221 valuation despite melanoma breakthrough.

What happened: Moderna (MRNA) reported encouraging Phase 3 data for intismeran autogene, an mRNA cancer drug made with Merck, showing significantly fewer melanomas returning in treated patients. Key numbers: 42% relative reduction in relapse or death. Analyst rates MRNA Strong Sell at $220.83, with working valuation of about $60 per share, implying 73% downside. Why it matters: The analyst sees commercial and manufacturing hurdles, persistent cash burn, and limited near-term product launches leaving a wide gap between pipeline optimism and current equity value.
Moderna (MRNA) reported encouraging Phase 3 data for intismeran autogene, an mRNA cancer drug made with Merck, showing significantly fewer melanomas returning in treated patients.
The analyst sees commercial and manufacturing hurdles, persistent cash burn, and limited near-term product launches leaving a wide gap between pipeline optimism and current equity value.
Sources